Published in Cancer Weekly, September 30th, 1996
Under a collaborative research agreement with the University, Cytoclonal exercised its first rights of refusal for the technology. Antisense products are under development to control genes involved in human diseases such as cancer, diabetes, or AIDS.
Antisense products bind to the disease related gene material to prevent it from causing the disease. Multiple human genes have been shown to be involved in human disease...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.